MarketCap
Facebook
X
Telegram
GT Biopharma Revenue | GTBP
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue GT Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 27 K | 61 K | 368 K | 342 K | 26 K | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 368 K | 26 K | 165 K |
Quarterly Revenue GT Biopharma
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20 K | 7 K | - | 3 K | 25 K | - | - | 183 K | 56 K | 88 K | - | 120 K | 1 K | 1 K | - | 2 K | 1 K | 20 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 183 K | 1 K | 40.5 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Exicure
XCUR
|
500 K | $ 1.05 | -1.85 % | $ 6.61 M |  USA |
 |
Cellectis S.A.
CLLS
|
72.9 M | $ 0.99 | 0.69 % | $ 99.3 M |  France |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 12.16 | 2.88 % | $ 3.63 B |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 59.01 | 1.7 % | $ 7.89 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 55.56 | -0.7 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
1.54 M | $ 29.4 | 0.5 % | $ 1.95 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.37 M | $ 3.78 | 3.0 % | $ 46.1 M |  Israel |
 |
Jaguar Health
JAGX
|
11.5 M | $ 2.34 | 14.46 % | $ 5.46 M | USA |
 |
Protalix BioTherapeutics
PLX
|
52.7 M | $ 2.49 | -2.55 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
16.1 M | $ 22.07 | -1.6 % | $ 1.27 B |  Niderland |
 |
Stoke Therapeutics
STOK
|
184 M | $ 25.29 | 1.0 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
126 M | $ 29.85 | 18.55 % | $ 2.22 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 1.77 | -0.56 % | $ 2.91 M | Israel |
 |
Incyte Corporation
INCY
|
5.14 B | $ 113.32 | -2.07 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
17.2 M | $ 12.44 | 1.3 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
81.4 M | $ 9.17 | -0.43 % | $ 738 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
12 B | $ 513.55 | -1.98 % | $ 131 B | USA |
 |
Altimmune
ALT
|
41 K | $ 2.07 | -2.36 % | $ 182 M | USA |
 |
Seagen
SGEN
|
1.96 B | - | - | $ 42.2 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 9.85 | 0.1 % | $ 270 M | Israel |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 31.72 | 1.67 % | $ 4.04 B | USA |
 |
Assembly Biosciences
ASMB
|
72.3 M | $ 19.86 | 0.1 % | $ 223 M | USA |
 |
Oncternal Therapeutics
ONCT
|
785 K | - | -24.12 % | $ 1.56 M | USA |
 |
ALX Oncology Holdings
ALXO
|
1.18 M | $ 1.14 | -2.99 % | $ 61.2 M | USA |
 |
Iterum Therapeutics
ITRM
|
37 K | - | - | $ 591 K |  Irlanda |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Achieve Life Sciences
ACHV
|
5.06 M | $ 6.58 | 1.36 % | $ 287 M | USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 245.73 | 0.97 % | $ 14.9 B |  Danmark |
 |
Alpine Immune Sciences
ALPN
|
58.9 M | - | - | $ 2.17 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
7.7 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
32.6 M | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
109 M | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
310 K | - | -8.77 % | $ 12.4 M | Israel |
 |
Histogen
HSTO
|
3.77 M | - | 31.6 % | $ 2.12 M | USA |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Cidara Therapeutics
CDTX
|
1.28 M | - | - | $ 1.41 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
77.1 M | $ 16.98 | 0.71 % | $ 2.28 B | Canada |
 |
Denali Therapeutics
DNLI
|
331 M | $ 18.52 | 0.6 % | $ 3.2 B | USA |
 |
Clovis Oncology
CLVS
|
36 M | - | -7.23 % | $ 13 M | USA |
 |
Kaleido Biosciences
KLDO
|
1.1 M | - | -3.69 % | $ 12.4 M | USA |
 |
Axon Enterprise
AXON
|
2.78 B | $ 418.83 | -0.37 % | $ 32.7 B | USA |
 |
PhaseBio Pharmaceuticals
PHAS
|
10.8 M | - | 7.4 % | $ 6.29 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
2.07 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Provention Bio
PRVB
|
12.9 M | - | - | $ 2.37 B | USA |
 |
Aptevo Therapeutics
APVO
|
3.11 M | $ 1.5 | -6.83 % | $ 473 K | USA |
 |
Reata Pharmaceuticals
RETA
|
2.22 M | - | - | $ 6.29 B | USA |
 |
PolarityTE
PTE
|
814 K | - | -0.82 % | $ 1.78 M | USA |